key: cord-0717555-a679opgx
authors: Destache, Christopher J.; Aurit, Sarah J.; Schmidt, David; Peet Erkes, Laura; Tierney, Maureen; Vivekanandan, Renuga
title: Bamlanivimab use in mild‐to‐moderate COVID‐19 disease: A matched cohort design
date: 2021-08-12
journal: Pharmacotherapy
DOI: 10.1002/phar.2613
sha: e9d6f300f9c8d92fc41a3182889db1a2bf9e8da8
doc_id: 717555
cord_uid: a679opgx

STUDY OBJECTIVE: Our objective was to determine if bamlanivimab (LY‐CoV555; BAM), a monoclonal antibody for mild‐to‐moderate Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Co‐V‐2, prevented emergency department (ED) visits, hospitalizations for SARS‐CoV‐2, or death within 60 days of a positive SARS‐CoV‐2 viral test. DESIGN: Patient propensity matching was performed for BAM administration to get two discrete groups of patients; those who received BAM (N = 117) and those who did not (N = 117). SETTING: Outpatients (N = 2107) eligible to receive BAM from November 1 to December 31, 2020, were identified. PATIENTS: A total of 144 of 2107 patients with mild‐to‐moderate SARS‐CoV‐2 received BAM INTERVENTION: Eligible patients had mild‐to‐moderate SARS‐CoV‐2 disease, a positive SARS‐CoV‐2 test, and risk factor(s) for progression to severe SARS‐CoV‐2 infection. All patients were reviewed for subsequent ED visits, subsequent hospitalization, and death. MEASUREMENTS AND MAIN RESULTS: Patients (N = 234) were matched, 117 in each group. Median (interquartile range) age was 72 (65–80) years. Forty‐seven percent of patients were male. Twenty‐one patients who received BAM were subsequently seen in the ED compared to 34 untreated patients (18.0% vs. 29.1%; p = 0.045). Fourteen BAM‐treated patients were subsequently hospitalized post‐BAM infusion compared to 27 untreated patients (12.0% vs. 23.1%; p = 0.025). Finally, there were no mortalities in the BAM group, however, eleven patients in the untreated group died (0.0% vs. 9.4%; p < 0.001). The number needed to treat (NNT) is 11 patients to prevent one mortality event. CONCLUSIONS: BAM infusion for mild‐to‐moderate SARS‐CoV‐2 infection in outpatients significantly prevented subsequent ED visits, hospitalizations, and death from SARS‐CoV‐2.

The United States Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to permit the administration of the unapproved product, bamlanivimab (LY-CoV555; BAM) for the treatment of mild-to-moderate severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) in adults and pediatric patients with a positive result of a SARS-CoV-2 viral test. Eligible patients must be over 12 years of age, weigh a minimum of 40 kg, and be at high risk for progressing to severe COVID-19 disease and/or hospitalization.

Bamlanivimab is a recombinant neutralizing human IgG1K monoclonal antibody that binds to the receptor-binding domain of the spike protein of SARS-CoV-2 and prevents the attachment of spike protein with the human angiotensin-converting enzyme-2 ACE2 receptor. 1 Benefit of treatment with this monoclonal antibody is to prevent hospitalization associated with COVID-19 viral illness; however, this remains unproven. Monoclonal antibodies are most effective when given early in infection. [2] [3] [4] The BLAZE-1 study reported SARS-CoV-2 viral load reductions at day 11 post-infusion of three escalating doses of BAM or one dose of the combination of BAM and etesevimab in a phase 2/3 clinical trial. 5 In the BLAZE-1 trial, a significant difference in the secondary endpoint that evaluated reduction in hospitalizations was found to be associated with combination treatment compared with placebo. High risk for progression and/or hospitalization was defined as having a minimum of one criterion from the following: a body mass index (BMI) ≥ 35; chronic kidney disease; diabetes; immunosuppressive illness; receiving immunosuppressive therapy; or age ≥55 years.

Our healthcare system had to surge COVID-19 cases and sought to determine if BAM treatment in patients with mild-to-moderate COVID-19 and risk factors for progression to severe infection impacted whether the patient subsequently required medical care through the Emergency Department (ED), acute hospitalization, or died from COVID-19 infection. We designed a retrospective analysis, which incorporated the review of the first 2 months (November and December 2020) of data from patients who received BAM treatment for outpatient mild-to-moderate SARS-CoV-2. The goal was to determine if this infusion was able to prevent ED utilization, hospitalization, or death from COVID-19 under the EUA.

All patients had mild-to-moderate SARS-CoV-2 as defined by SARS-CoV-2 signs and symptoms, a positive SARS-CoV-2 test, and were seen as outpatients. Additionally, patients had at least one risk factor for the development of severe COVID-19 infection or hospitalization. Risk factors were defined according to the FDA Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab. 1 A report was generated from the health system electronic medical record of all patients from November 1 to December 31, 2020, who had a positive SARS-CoV-2 PCR test and at least one of the following risk factors: age greater or equal to 65 years, BMI greater than or equal to 35, chronic kidney disease, diabetes, immunosuppressive disease, immunosuppressive treatment, age greater than or equal to 55 years and cardiovascular disease, age greater than or equal to 55 years and hypertension, age greater than or equal to 55 years and chronic respiratory pulmonary disease or other chronic respiratory diseases, or age less than 55 years with sickle cell disease, congenital or acquired heart disease, neurodevelopment disorders, medical-related technological device dependence, asthma, or reactive airway disease. Patients identified in this report were then searched to determine if they received BAM treatment as part of their COVID-19 infection treatment. Exclusion criteria for antibody infusion included hospitalization due to COVID-19; oxygen therapy required due to COVID-19; baseline oxygen flow rate increase due to COVID-19 in those on chronic oxygen therapy due to non-COVID-19-related comorbidity.

The work described has been carried out in accordance with The Code of Ethics (Declaration of Helsinki) (IRB #2001755). Informed consent was not required from patients given the retrospective nature of the study design.

Patients who met eligibility criteria were identified and their electronic medical records (EHR; EPIC) were reviewed to determine if subsequent hospitalization or an ED visit occurred after the date of their antibody infusion specifically for SARS-CoV-2 or within 60 days after the positive SARS-CoV-2 viral test. These data were assimilated for patients who received antibody treatment and for those who did not receive treatment.

Demographic and clinical characteristics of the entire cohort are presented in the Table S1. In the entire cohort, patients who received BAM treatment were older and were more likely to have received immunosuppressive treatment, be older than 55 years and have cardiovascular disease, hypertension, or chronic renal disease, and were also more likely to have acquired or congenital heart disease. Based on these results of the cohort, it was felt that matching BAM and control patients would be appropriate. Patients who received BAM treatment (n = 144) were matched to non-treated patients (n = 1963) to create two balanced mutually exclusive groups.

Propensity scores, defined as the probability of receiving treatment conditional on observed variables of interest, were calculated.

Patients with a minimum score of 0.05 with non-missing BMI were considered eligible for an optimal 1:1 match without replacement. [6] [7] [8] [9] The matching algorithm included an exact match of biological sex in conjunction with matching based upon age via Mahalanobis distance for that a pooled covariance matrix was considered. 10 Assessment of post-match balance was conducted by examining standardized differences of reactive airway disease, asthma, technology-dependent, neurodevelopment disability, acquired or congenital heart disease, sickle cell disease, chronic respiratory disease, hypertension, cardiovascular disease, immunosuppressive disease status and treatment, diabetes, chronic kidney disease, calculated risk score, BMI, and age.

Continuous variables are presented as median and interquartile range (IQR), whereas discrete variables are presented as counts and

proportions. Comparisons of patients, contingent upon treatment status, were made with the Mann-Whitney test for continuous variables and the chi-square or Fisher's exact test for discrete variables contingent upon expected frequencies. The subsequent occurrence of a hospitalization or an ED visit for SARS-CoV-2 was modeled with a binary logistic regression model that allowed for the adjustment of immunosuppressive disease treatment. We initially fit models that considered the nesting of patients within each geographic location; however, there were not enough data to obtain convergence. Given the lack of mortality events within the monoclonal antibody infusion group, it was not possible to generate a multivariable model. Instead, a comparison of crude mortality rates is presented, which were calculated alongside exact 95% confidence intervals (CI). In conclusion, our results demonstrate that BAM infusion significantly prevented ED visits and hospitalizations in SARS-CoV-2 patients with risk factors for progression. Additionally, the NNT of 11 demonstrates that BAM infusion was able to significantly prevent mortality from SARS-CoV-2 infection. These results are similar to or better than other preventive initiatives. [15] [16] [17] [18] [19] 

The authors declare no conflicts of interest.

Collected data and wrote initial draft of manuscript CJD; analyzed data statistically SA; initial idea and edited manuscript DS and LPE;

Edited manuscript RV and MT.

Christopher J. Destache https://orcid.org/0000-0001-7923-3939

Christopher J. Destache @CUIDRX

Fact sheet for health care providers emergency use authorization of bamlanivimab

Mild clinical course of covid-19 in 3 patients receiving therapeutic monoclonal antibodies targeting c5 complement for hematologic disorders

Monoclonal antibodies for prevention and treatment of covid-19

Vaccines, convalescent plasma, and monoclonal antibodies for covid-19

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate covid-19: a randomized clinical trial

The bias due to incomplete matching

Rare outcomes, common treatments: Analytic strategies using propensity scores

Invited commentary: propensity scores

Directional penalties for optimal matching in observational studies

SAS: Covariance matrix

Effect of bamlanivimab vs placebo on incidence of covid-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial

Covid antibody treatments show promise for preventing severe disease

Neutralising antibody escape of sars-cov-2 spike protein: risk assessment for antibody-based covid-19 therapeutics and vaccines

Subcutaneous regencov antibody combination for covid-19 prevention. medRxiv

Corticosteroids for pneumonia. Cochrane Database Syst Rev

Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease

The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and hcv genotype 1 infection

Lower liver cancer risk with antiviral therapy in chronic hepatitis b patients with normal to minimally elevated alt and no cirrhosis

Cotrimoxazole for prophylaxis or treatment of opportunistic infections of hiv/aids in patients with previous history of hypersensitivity to cotrimoxazole